Drug Approval | May 06, 2024
Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Subscribe To Our Newsletter & Stay Updated
